We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+0.15%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$474M
AUM Growth
+$427M
Cap. Flow
+$433M
Cap. Flow %
91.18%
Top 10 Hldgs %
10.55%
Holding
454
New
296
Increased
64
Reduced
55
Closed
20

Top Buys

Rank Stock Value
1
OXLC
Oxford Lane Capital
OXLC
+$6.86M
2
BBDC icon
Barings BDC
BBDC
+$6.33M
3
OXSQ icon
Oxford Square Capital
OXSQ
+$5.45M
4
ECC
Eagle Point Credit Company
ECC
+$5.29M
5
FSK icon
FS KKR Capital
FSK
+$5.24M

Top Sells

Rank Stock Value
1
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$2.25M
2
ACOR
Acorda Therapeutics
ACOR
+$644K
3
ARRY
Array Biopharma Inc
ARRY
+$605K
4
NITE
Nightstar Therapeutics plc American Depositary Shares
NITE
+$603K
5
QURE icon
uniQure
QURE
+$374K

Sector Composition

Rank Sector Weight
1 Financials 23.58%
2 Real Estate 14.99%
3 Energy 13.55%
4 Healthcare 12.23%
5 Materials 8.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLVS
151
DELISTED
Clovis Oncology, Inc.
CLVS
$930K 0.2%
+62,509
New +$1.13M
LXRX icon
152
Lexicon Pharmaceuticals
LXRX
$1.02B
$901K 0.19%
+143,272
New +$858K
RARE icon
153
Ultragenyx Pharmaceutical
RARE
$2.65B
$899K 0.19%
14,162
-2,223
-14% -$141K
ALXN
154
DELISTED
Alexion Pharmaceuticals
ALXN
$899K 0.19%
+6,864
New +$885K
RDUS
155
DELISTED
Radius Health, Inc.
RDUS
$896K 0.19%
+36,795
New +$804K
ACAD icon
156
Acadia Pharmaceuticals
ACAD
$4.25B
$892K 0.19%
+33,367
New +$852K
FOLD
157
DELISTED
Amicus Therapeutics
FOLD
$890K 0.19%
71,320
-2,333
-3% -$29.6K
INCY icon
158
Incyte
INCY
$23.5B
$885K 0.19%
10,417
-1,096
-10% -$88K
HALO icon
159
Halozyme
HALO
$9.72B
$884K 0.19%
51,461
+626
+1% +$10.1K
EXEL icon
160
Exelixis
EXEL
$13.9B
$878K 0.19%
41,091
+4,650
+13% +$97.5K
STML
161
DELISTED
Stemline Therapeutics, Inc.
STML
$875K 0.18%
57,127
+30,273
+113% +$438K
VRTX icon
162
Vertex Pharmaceuticals
VRTX
$121B
$872K 0.18%
4,756
+329
+7% +$57.5K
NKTR icon
163
Nektar Therapeutics
NKTR
$2.39B
$870K 0.18%
+1,631
New +$818K
GILD icon
164
Gilead Sciences
GILD
$161B
$864K 0.18%
+12,794
New +$842K
LGND icon
165
Ligand Pharmaceuticals
LGND
$6.02B
$860K 0.18%
12,080
+3,259
+37% +$240K
BMRN icon
166
BioMarin Pharmaceuticals
BMRN
$11.5B
$858K 0.18%
10,013
+1,728
+21% +$148K
IRWD icon
167
Ironwood Pharmaceuticals
IRWD
$611M
$854K 0.18%
78,060
-4,100
-5% -$45.9K
PTLA
168
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$853K 0.18%
+31,436
New +$986K
SAGE
169
DELISTED
Sage Therapeutics
SAGE
$850K 0.18%
4,645
+2,000
+76% +$341K
AMGN icon
170
Amgen
AMGN
$203B
$847K 0.18%
+4,597
New +$823K
TVTX icon
171
Travere Therapeutics
TVTX
$5.33B
$847K 0.18%
+42,161
New +$832K
MNTA
172
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$841K 0.18%
67,570
-1,745
-3% -$23.2K
AGIO icon
173
Agios Pharmaceuticals
AGIO
$2.16B
$840K 0.18%
16,847
+2,307
+16% +$123K
ALNY icon
174
Alnylam Pharmaceuticals
ALNY
$36.3B
$839K 0.18%
11,559
+1,297
+13% +$99.5K
IONS icon
175
Ionis Pharmaceuticals
IONS
$9.35B
$838K 0.18%
+13,037
New +$922K
5 6
7
8 9

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
ALS
Andrew L. Share $214M AUM 14.75% 1-Year Est. Return

Virtus ETF Advisers's Q2 2019 Portfolio in Review

As of Q2 2019, Virtus ETF Advisers held 454 positions worth $474M, up 909% from $47M the previous quarter. Its ten largest holdings account for 11% of the portfolio.

Virtus ETF Advisers deployed $433M of net new capital in Q2 2019, opening 296 new positions and adding to 64 existing holdings. Its largest new stake was Oxford Lane Capital: 132,284 shares worth $6.67M.

By sector, the portfolio is most concentrated in Financials at 24% of assets, up from 0.73% a quarter earlier, followed by Real Estate and Energy.

On the sell side, the largest reduction was Array Biopharma Inc, an estimated $605K trimmed.

  • Virtus ETF Advisers's largest Q2 2019 buy was Oxford Lane Capital: 132,284 shares worth $6.67M.
  • Virtus ETF Advisers added most to Dominion Energy in Q2 2019, an estimated $2.63M increase.
  • Virtus ETF Advisers's biggest Q2 2019 reduction was Array Biopharma Inc, cutting an estimated $605K.
  • Virtus ETF Advisers fully exited Spark Therapeutics, Inc. Common Stock in Q2 2019, selling an estimated $2.25M.
  • Virtus ETF Advisers's ten largest holdings make up 11% of its $474M portfolio in Q2 2019.
  • Virtus ETF Advisers opened 296 new positions and closed 20 in Q2 2019.
  • Virtus ETF Advisers's portfolio value rose 909% quarter-over-quarter to $474M.

Based on Virtus ETF Advisers's 13F filing for Q2 2019, filed 13 Aug 2019.